Cystinosis News and Research

RSS
Cystinosis is a condition in which the body accumulates the amino acid cystine (a building block of proteins) within cells. Excess cystine forms crystals that can build up and damage cells. These crystals negatively affect many systems in the body, especially the kidneys and eyes.
Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

FDA accepts for filing Sigma-Tau Pharmaceuticals' cysteamine hydrochloride ophthalmic solution NDA

FDA accepts for filing Sigma-Tau Pharmaceuticals' cysteamine hydrochloride ophthalmic solution NDA

Raptor Pharmaceutical presents positive results from Phase 2a trial of DR cysteamine bitartrate for NASH

Raptor Pharmaceutical presents positive results from Phase 2a trial of DR cysteamine bitartrate for NASH

Raptor Pharmaceutical engages The Trout Group for strategic advisory and investor relations services

Raptor Pharmaceutical engages The Trout Group for strategic advisory and investor relations services

Raptor Pharmaceutical to present DR Cysteamine trial data at Lysosomal Disease Network Symposium

Raptor Pharmaceutical to present DR Cysteamine trial data at Lysosomal Disease Network Symposium

Results from Phase 2a clinical trial of Raptor Pharmaceutical's cysteamine bitartrate published

Results from Phase 2a clinical trial of Raptor Pharmaceutical's cysteamine bitartrate published

CRF awards $1.75 million in 11 new grants to researchers to find a cure for cystinosis

CRF awards $1.75 million in 11 new grants to researchers to find a cure for cystinosis

Raptor Pharmaceutical completes $7.5 million registered direct offering

Raptor Pharmaceutical completes $7.5 million registered direct offering

Raptor Pharmaceutical enters into definitive agreements with institutional investors to purchase 3.7M units

Raptor Pharmaceutical enters into definitive agreements with institutional investors to purchase 3.7M units

Raptor Pharmaceutical announces Phase 2b results of DR Cysteamine trial

Raptor Pharmaceutical announces Phase 2b results of DR Cysteamine trial

Raptor Pharmaceutical announces results of NGX426 clinical trial

Raptor Pharmaceutical announces results of NGX426 clinical trial

Raptor Pharmaceutical to present oral AMPA-kainate antagonist data at the neuropathic pain conference

Raptor Pharmaceutical to present oral AMPA-kainate antagonist data at the neuropathic pain conference

Results of Phase 2a clinical trial of DR Cysteamine announced by Raptor Pharmaceutical

Results of Phase 2a clinical trial of DR Cysteamine announced by Raptor Pharmaceutical

Raptor Pharmaceutical appoints Llew Keltner to its board of directors

Raptor Pharmaceutical appoints Llew Keltner to its board of directors

Raptor and TorreyPines Therapeutics announce merger completion

Raptor and TorreyPines Therapeutics announce merger completion

Raptor Pharmaceuticals raises funds to execute its corporate strategy

Raptor Pharmaceuticals raises funds to execute its corporate strategy

Brain-derived neurotrophic factor may predict schizophrenia relapse

Brain-derived neurotrophic factor may predict schizophrenia relapse

Raptor Pharmaceuticals initiates phase IIa clinical study for Convivia

Raptor Pharmaceuticals initiates phase IIa clinical study for Convivia

Powerful new discovery method speeds up gene discovery

Powerful new discovery method speeds up gene discovery

Promising treatment for Huntington's disease soon to be tested clinically

Promising treatment for Huntington's disease soon to be tested clinically